<DOC>
	<DOCNO>NCT01627704</DOCNO>
	<brief_summary>Compare response rate 6 month hormone treatment ( major change hormone treatment ) metastatic breast cancer , accord uptake FES metastatic lesion taking-up FDG PET/CT baseline . Hypothesis : best response rate observe patient metastasis take FES prior treatment .</brief_summary>
	<brief_title>Fluoroestradiol PET Imaging Predicting Response Hormone Therapy Breast Cancer</brief_title>
	<detailed_description>Main objective : Compare response rate 6 month hormone treatment ( major change hormone treatment ) metastatic breast cancer , accord uptake FES metastatic lesion taking-up FDG PET/CT baseline . Secondary objective : - evaluate diagnostic performance FES PET/CT - determine whether FES PET/CT able detect metastasis visible FDG PET/CT . This point may constitute direct benefit patient - precise nature discordant FES/FDG focus - validate improve interpretation criterion FES PET/CT - confirm perfect tolerance</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Post menopausal age &gt; 17 WHO 02 Metastatic adenocarcinoma breast Treated antihormone treatment around 5 year withdraw least 3 month OR metastatic cancer diagnosis receive one line hormone treatment Life expectancy &gt; 6 month Hormonedependent cancer initially demonstrate hormone receptor tumour Presence oestrogen receptor prove immunohistochemistry ( &gt; 10 % ) HER2 determine immunohistochemistry FISH ( primary tumour metastasis ) Metastatic recurrence FDG PET date less 1 month , confirm another modality ( contrastenhanced CT , MRI , ultrasonography , bone scintigraphy PET/CT , ) FDG PET/CT available PACS CD DICOM III format 11 Informed consent obtain Other evolutive malignant disease acute chronic infectious disease Chemotherapy last 3 month change treatment since FDG PET/CT . Isolated liver metastasis ( high FES uptake normal liver )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>PET/CT , fluoroestradiol ( 18F )</keyword>
	<keyword>breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>prediction response</keyword>
	<keyword>hormone therapy</keyword>
</DOC>